American Express (AXP) “Buy” Rating Reaffirmed at Sandler O’Neill; With $113.0 Target; Algorx Pharmaceuticals Has 1.35 Sentiment

January 17, 2018 - By Ellis Scott

Among 35 analysts covering American Express Company (NYSE:AXP), 9 have Buy rating, 4 Sell and 22 Hold. Therefore 26% are positive. American Express Company has $130.0 highest and $54 lowest target. $92.21’s average target is -8.10% below currents $100.34 stock price. American Express Company had 98 analyst reports since July 23, 2015 according to SRatingsIntel. Morgan Stanley maintained American Express Company (NYSE:AXP) rating on Thursday, July 20. Morgan Stanley has “Equal-Weight” rating and $90 target. The company was upgraded on Monday, January 30 by Keefe Bruyette & Woods. JP Morgan upgraded the shares of AXP in report on Tuesday, January 17 to “Overweight” rating. Goldman Sachs maintained the shares of AXP in report on Tuesday, June 7 with “Neutral” rating. The firm has “Underperform” rating by Macquarie Research given on Thursday, April 21. The stock has “Neutral” rating by Goldman Sachs on Thursday, April 21. The stock of American Express Company (NYSE:AXP) has “Buy” rating given on Thursday, October 19 by Bank of America. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, October 19 report. The company was downgraded on Monday, October 26 by UBS. The stock of American Express Company (NYSE:AXP) earned “Neutral” rating by Goldman Sachs on Wednesday, January 13.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $119.31 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

American Express Company, together with its subsidiaries, provides charge and credit payment card products and travel-related services to clients and businesses worldwide. The company has market cap of $87.10 billion. It operates through four divisions: U.S. It has a 19.43 P/E ratio. Consumer Services, International Consumer and Network Services, Global Commercial Services, and Global Merchant Services.

Analysts await American Express Company (NYSE:AXP) to report earnings on January, 18 after the close. They expect $1.54 earnings per share, up 69.23% or $0.63 from last year’s $0.91 per share. AXP’s profit will be $1.34 billion for 16.29 P/E if the $1.54 EPS becomes a reality. After $1.50 actual earnings per share reported by American Express Company for the previous quarter, Wall Street now forecasts 2.67% EPS growth.

Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.01, from 0.82 in 2017Q2. It is positive, as 47 investors sold American Express Company shares while 434 reduced holdings. 100 funds opened positions while 297 raised stakes. 709.03 million shares or 0.92% less from 715.61 million shares in 2017Q2 were reported. 4,536 are held by Spinnaker. M&R Capital Management Incorporated accumulated 0.08% or 3,540 shares. Liberty Capital Mgmt accumulated 600 shares. Mufg Americas Hldgs Corporation stated it has 0.56% of its portfolio in American Express Company (NYSE:AXP). Willis Investment Counsel, a Georgia-based fund reported 98,255 shares. Tci Wealth has invested 0.19% in American Express Company (NYSE:AXP). Korea Inv, a Korea-based fund reported 669,027 shares. Matrix Asset Advisors New York reported 1.58% of its portfolio in American Express Company (NYSE:AXP). Blackrock accumulated 42.31M shares. Regions Financial owns 239,441 shares. Profund Advsrs Ltd Company holds 24,477 shares or 0.09% of its portfolio. Parnassus Ca reported 0.85% of its portfolio in American Express Company (NYSE:AXP). Ronna Sue Cohen has 2,500 shares for 0.17% of their portfolio. Us-based Ancora Advisors Ltd Limited Liability Company has invested 0.02% in American Express Company (NYSE:AXP). Lenox Wealth Advsrs has invested 0% of its portfolio in American Express Company (NYSE:AXP).

The stock decreased 0.62% or $0.63 during the last trading session, reaching $100.34. About 3.81M shares traded or 19.13% up from the average. American Express Company (NYSE:AXP) has risen 22.41% since January 17, 2017 and is uptrending. It has outperformed by 5.71% the S&P500.

Since July 31, 2017, it had 0 insider purchases, and 11 insider sales for $38.86 million activity. Sobbott Susan also sold $506,340 worth of American Express Company (NYSE:AXP) on Thursday, September 7. The insider Williams Anre D sold $2.87M. Shares for $4.32M were sold by O’Neill Michael John. Bush James Peter sold $1.27 million worth of American Express Company (NYSE:AXP) on Tuesday, January 2. Buckminster Douglas E. sold $8.79M worth of American Express Company (NYSE:AXP) on Monday, December 11. 3,196 shares were sold by Zukauckas Linda, worth $304,962. Another trade for 96,440 shares valued at $9.38M was sold by CHENAULT KENNETH I.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.25 earnings per share, up 13.79% or $0.04 from last year’s $-0.29 per share. After $-0.22 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.64% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: